Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.

de Prost D, Barbier-Boehm G, Hazebroucq J, Ibrahim H, Bielsky MC, Hvass U, Lacombe C, Français JL, Desmonts JM

Thrombosis and haemostasis1 Aug 1992Cited by 28 (Europe PMC)

PMID1412152DOI10.1055/s-0038-1656332PepBankPUB-01412152

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients bleeding after cardiopulmonary bypass, desmopressin and placebo produced similar blood loss.
In plain wordsAfter cardiopulmonary bypass, blood loss was similar with desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeBlood loss during first 24 hours
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Blood loss
582 ml
desmopressin
Blood loss
465 ml
placebo
p
0.15
between groups
Source sentences
Summary
Mean blood loss during the first 24 h post-treatment was similar in the desmopressin and placebo groups (582 vs 465 ml, respectively; p = 0.15).
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215201
02HumanRandomized controlled trialEfficacy outcome
In patients bleeding after cardiopulmonary bypass, red-cell requirements were similar with desmopressin and placebo.
In plain wordsAfter cardiopulmonary bypass, red-cell requirements were similar with desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeRed-cell requirements
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
p
0.76
red-cell requirements
Source sentences
Summary
Red-cell (p = 0.76), fresh frozen plasma (r = 0.66) and platelet unit (p = 0.74) requirements were also similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215202
03HumanRandomized controlled trialEfficacy outcome
In patients bleeding after cardiopulmonary bypass, plasma requirements were similar with desmopressin and placebo.
In plain wordsAfter cardiopulmonary bypass, plasma requirements were similar with desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeFresh frozen plasma requirements
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
r
0.66
fresh frozen plasma requirements
Source sentences
Summary
Red-cell (p = 0.76), fresh frozen plasma (r = 0.66) and platelet unit (p = 0.74) requirements were also similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215203
04HumanRandomized controlled trialEfficacy outcome
In patients bleeding after cardiopulmonary bypass, platelet requirements were similar with desmopressin and placebo.
In plain wordsAfter cardiopulmonary bypass, platelet requirements were similar with desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changePlatelet unit requirements
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
p
0.74
platelet requirements
Source sentences
Summary
Red-cell (p = 0.76), fresh frozen plasma (r = 0.66) and platelet unit (p = 0.74) requirements were also similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215204
05HumanRandomized controlled trialMechanism
After cardiopulmonary bypass, vWF was slightly higher with desmopressin than placebo at 90 min, without a significant difference.
In plain wordsAfter cardiopulmonary bypass, vWF did not differ significantly between desmopressin and placebo at 90 min.
Peptide
Desmopressin
Outcome
No significant changevon Willebrand factor at 90 minutes
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Source sentences
Summary
although vWF and factor VIII:C levels were slightly higher in desmopressin-treated patients at 90 min, the difference was not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215205
06HumanRandomized controlled trialMechanism
After cardiopulmonary bypass, factor VIII:C was slightly higher with desmopressin than placebo at 90 min, without a significant difference.
In plain wordsAfter cardiopulmonary bypass, factor VIII:C did not differ significantly between desmopressin and placebo at 90 min.
Peptide
Desmopressin
Outcome
No significant changeFactor VIII:C at 90 minutes
Study
n = 92
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kg · intravenousAs given in this study (human).
Source sentences
Summary
although vWF and factor VIII:C levels were slightly higher in desmopressin-treated patients at 90 min, the difference was not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 micrograms/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.
Report a problemFND-0141215206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.